BRTX BioRestorative Therapies Announces Complia
Post# of 72353
(Total Views: 35)
Posted On: 05/03/2021 9:53:02 AM
BRTX
BioRestorative Therapies Announces Compliance with SEC Reporting Requirements and "Stop Sign" Removal
6:00 am ET May 3, 2021 (Globe Newswire) Print
BioRestorative Therapies, Inc. (the "Company" or "BioRestorative"
(OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2020 and, as a result, is now current in its SEC periodic filings. The filing of the Form 10-K has resulted in the removal of the "stop sign" from the OTC Markets website with regard to the Company, indicating that BioRestorative now has current public information available.
Lance Alstodt, Chairman and CEO, stated "I am very excited that, after only 5 months post- Chapter 11, we are now current in all of our reporting requirements with the SEC. It is a testament to the execution of our team and advisors, having met an aggressive timetable in achieving this meaningful milestone. We believe that we are now very well positioned to pursue funding opportunities to initiate our phase 2 clinical trial, which the FDA has granted us approval to begin. Additionally, we will advance our metabolics program simultaneously, continuing to build fundamental value within our two platform technologies.
The Company is now at a critical inflection point where value creation should largely be tied to the advancement of our clinical programs. I'm pleased with our team's discipline and focus, accomplishing so much in a short period of time. Among the many goals we have met: we have right sized the organization with a more efficient infrastructure reducing our monthly burn rate; we have recapitalized our balance sheet to include a more flexible set of future funding opportunities; and we have added to our team of experts and advisors to match our challenges with the right set of human resources. Leveraging all of these corporate activities will position BioRestorative as a biotechnology company with many future operational/clinical catalysts to drive value to our shareholders. I'm passionate about our technology and our ability to prove and validate what could be paradigm shifting events in the sectors where we focus."
Francisco Silva, Vice President of Research and Development, added, "Achieving full reporting compliance was an important milestone for the company; we can now turn our attention to initiating our clinical programs. We expect to address in-house clinical manufacturing capabilities for both our ThermoStem(R) metabolic and BRTX-100(R) disc/spine programs. We look forward to achieving our clinical targets and driving value based on clinical catalysts".
About BioRestorative Therapies, Inc.
BioRestorative Therapies Announces Compliance with SEC Reporting Requirements and "Stop Sign" Removal
6:00 am ET May 3, 2021 (Globe Newswire) Print
BioRestorative Therapies, Inc. (the "Company" or "BioRestorative"
(OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2020 and, as a result, is now current in its SEC periodic filings. The filing of the Form 10-K has resulted in the removal of the "stop sign" from the OTC Markets website with regard to the Company, indicating that BioRestorative now has current public information available. Lance Alstodt, Chairman and CEO, stated "I am very excited that, after only 5 months post- Chapter 11, we are now current in all of our reporting requirements with the SEC. It is a testament to the execution of our team and advisors, having met an aggressive timetable in achieving this meaningful milestone. We believe that we are now very well positioned to pursue funding opportunities to initiate our phase 2 clinical trial, which the FDA has granted us approval to begin. Additionally, we will advance our metabolics program simultaneously, continuing to build fundamental value within our two platform technologies.
The Company is now at a critical inflection point where value creation should largely be tied to the advancement of our clinical programs. I'm pleased with our team's discipline and focus, accomplishing so much in a short period of time. Among the many goals we have met: we have right sized the organization with a more efficient infrastructure reducing our monthly burn rate; we have recapitalized our balance sheet to include a more flexible set of future funding opportunities; and we have added to our team of experts and advisors to match our challenges with the right set of human resources. Leveraging all of these corporate activities will position BioRestorative as a biotechnology company with many future operational/clinical catalysts to drive value to our shareholders. I'm passionate about our technology and our ability to prove and validate what could be paradigm shifting events in the sectors where we focus."
Francisco Silva, Vice President of Research and Development, added, "Achieving full reporting compliance was an important milestone for the company; we can now turn our attention to initiating our clinical programs. We expect to address in-house clinical manufacturing capabilities for both our ThermoStem(R) metabolic and BRTX-100(R) disc/spine programs. We look forward to achieving our clinical targets and driving value based on clinical catalysts".
About BioRestorative Therapies, Inc.
(0)
(0)